Blog
RSS FeedPosted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 10 Sep 2024
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer
29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Sep 2024
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with unresectable advanced, claudin 18.2 positive HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
9 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...
Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 10 Aug 2024
Two new treatment options for incurable blood cancer assessed
9 August 2024 - We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 07 Aug 2024
Durvalumab in combination with chemotherapy before surgery (neo-adjuvant) then alone after surgery (adjuvant) for the treatment of adults with resectable non-small-cell lung cancer
30 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2024
First targeted treatment made available for hundreds of blood cancer patients on the NHS
1 August 2024 - A take at home tablet which could be a ‘game-changer’ for hundreds of blood cancer patients ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...